Biogen’s therapy previously secured an orphan drug designation for FA treatment. Credit: Piotr Swat/Shutterstock. Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat
AstraZeneca will leverage Alteogen’s platform technology to develop the therapies. Credit: © AstraZeneca 2025. AstraZeneca has entered an exclusive licence agreement with bio-platform company Alteogen,
The company has recently shared Phase I outcomes for an orally administered candidate for non-opioid pain relief. Credit: meeboonstudio/Shutterstock. Latigo Biotherapeutics has secured $150m in
Azurity’s mission of serving overlooked individuals is further advanced through the acquisition. Credit: JHVEPhoto/Shutterstock. Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the
BMS’ Breyanzi has gained approval for several other lymphomas in the EU and other regions. Credit: Piotr Swat/Shutterstock. The European Commission (EC) has granted expanded
The Swedish company aims to expedite drug discovery via in-house and collaborated pipelines. Credit: Tapati Rinchumrus/Shutterstock. Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a
The drug is being jointly developed and commercialised through a partnership between Lundbeck and Otsuka. Credit: Longfin Media/Shutterstock. The European Commission (EC) has approved Otsuka
The company plans to refine its AI models and algorithms and widen its automated laboratory. Credit: raker/Shutterstock. Insilico Medicine has completed a Series E financing
Rocketvax focuses on developing next-generation vaccines using its molecular biology technologies. Credit: Pormezz/Shutterstock. Emergent BioSolutions has entered a strategic financial investment agreement with Swiss Rockets
The company is preparing to progress the drug into a registrational Phase III trial for subjects with mesothelioma. Credit: PowerUp/Shutterstock. Vivace Therapeutics has closed $35m